The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Monoclonal antibody therapeutics: history and future
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
Rapid generation of functional human IgG antibodies derived from Fab-on-phage display libraries
Jostock, T., Vanhove, M., Brepoels, E., van Gool, R., Daukandt, M., Wehnert, A., van Hegelsom, R., Dransfield, D., Sexton, D., Devlin, M., et al. (2004) · Journal of Immunological Methods · doi:10.1016/j.jim.2004.03.014 · Cited by 2,572
Phage antibodies: filamentous phage displaying antibody variable domains
McCafferty, J., Griffiths, A. D., Winter, G., & Chiswell, D. J. (1990) · Nature · doi:10.1038/348552a0 · Cited by 2,423
Making antibodies by phage display technology
Winter, G., Griffiths, A. D., Hawkins, R. E., & Hoogenboom, H. R. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.002245 · Cited by 1,573
Replacing the complementarity-determining regions in a human antibody with those from a mouse
Jones, P. T., Dear, P. H., Foote, J., Neuberger, M. S., & Winter, G. (1986) · Nature · doi:10.1038/321522a0 · Cited by 1,406
Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains.
Morrison, S. L., Johnson, M. J., Herzenberg, L. A., & Oi, V. T. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.21.6851 · Cited by 1,039
Vaughan, T. J., Williams, A. J., Pritchard, K., Osbourn, J. K., Pope, A. R., Earnshaw, J. C., McCafferty, J., Hodits, R. A., Wilton, J., & Johnson, K. S. (1996) · Nature Biotechnology · doi:10.1038/nbt0396-309 · Cited by 1,027
Development trends for human monoclonal antibody therapeutics
Nelson, A. L., Dhimolea, E., & Reichert, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3229 · Cited by 1,026
Shen, B.-Q., Xu, K., Liu, L., Raab, H., Bhakta, S., Kenrick, M., Parsons-Reponte, K. L., Tien, J., Yu, S.-F., Mai, E., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2108 · Cited by 1,008
Therapeutic antibodies for autoimmunity and inflammation
Chan, A. C., & Carter, P. J. (2010) · Nature Reviews Immunology · doi:10.1038/nri2761 · Cited by 837
Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target
Yu, Y. J., Zhang, Y., Kenrick, M., Hoyte, K., Luk, W., Lu, Y., Atwal, J., Elliott, J. M., Prabhu, S., Watts, R. J., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002230 · Cited by 794
Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn)
Dall'Acqua, W. F., Kiener, P. A., & Wu, H. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604292200 · Cited by 646
Hamann, P. R., Hinman, L. M., Hollander, I., Beyer, C. F., Lindh, D., Holcomb, R., Hallett, W., Tsou, H.-R., Upeslacis, J., Shochat, D., et al. (2002) · Bioconjugate Chemistry · doi:10.1021/bc010021y · Cited by 594
Production of functional chimaeric mouse/human antibody
Boulianne, G. L., Hozumi, N., & Shulman, M. J. (1984) · Nature · doi:10.1038/312643a0 · Cited by 550
Junttila, T. T., Li, G., Parsons, K., Phillips, G. L., & Sliwkowski, M. X. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1090-x · Cited by 541
Ober, R. J., Radu, C. G., Ghetie, V., & Ward, E. S. (2001) · International Immunology · doi:10.1093/intimm/13.12.1551 · Cited by 501
Hybrid antibodies can target sites for attack by T cells
Staerz, U. D., Kanagawa, O., & Bevan, M. J. (1985) · Nature · doi:10.1038/314628a0 · Cited by 492
Contribution of Linker Stability to the Activities of Anticancer Immunoconjugates
Alley, S. C., Benjamin, D. R., Jeffrey, S. C., Okeley, N. M., Meyer, D. L., Sanderson, R. J., & Senter, P. D. (2008) · Bioconjugate Chemistry · doi:10.1021/bc7004329 · Cited by 479
Getting into the Brain: Approaches to Enhance Brain Drug Delivery
Patel, M. M., Goyal, B. R., Bhadada, S. V., Bhatt, J. S., & Amin, A. F. (2009) · CNS Drugs · doi:10.2165/0023210-200923010-00003 · Cited by 461
A Theoretical Model of γ-Globulin Catabolism
BRAMBELL, F. W. R., HEMMINGS, W. A., & MORRIS, I. G. (1964) · Nature · doi:10.1038/2031352a0 · Cited by 449
Aalberse, R. C., & Schuurman, J. (2002) · Immunology · doi:10.1046/j.0019-2805.2001.01341.x · Cited by 449
Stemmler, H.-J., Schmitt, M., Willems, A., Bernhard, H., Harbeck, N., & Heinemann, V. (2007) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000236313.50833.ee · Cited by 412
Antigen-specific human antibodies from mice comprising four distinct genetic modifications
Lonberg, N., Taylor, L. D., Harding, F. A., Trounstine, M., Higgins, K. M., Schramm, S. R., Kuo, C.-C., Mashayekh, R., Wymore, K., McCabe, J. G., et al. (1994) · Nature · doi:10.1038/368856a0 · Cited by 398
Immunogenicity of protein therapeutics: The key causes, consequences and challenges
Baker, M., Reynolds, H. M., Lumicisi, B., & Bryson, C. J. (2010) · Self/Nonself · doi:10.4161/self.1.4.13904 · Cited by 372
Green, L. L., Hardy, M. C., Maynard-Currie, C. E., Tsuda, H., Louie, D. M., Mendez, M. J., Abderrahim, H., Noguchi, M., Smith, D. H., Zeng, Y., et al. (1994) · Nature Genetics · doi:10.1038/ng0594-13 · Cited by 355
Hoet, R. M., Cohen, E. H., Kent, R. B., Rookey, K., Schoonbroodt, S., Hogan, S., Rem, L., Frans, N., Daukandt, M., Pieters, H., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1067 · Cited by 315
Pestalozzi, B. C., & Brignoli, S. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.11.2349 · Cited by 301
Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo
Labrijn, A. F., Buijsse, A. O., van den Bremer, E. T. J., Verwilligen, A. Y. W., Bleeker, W. K., Thorpe, S. J., Killestein, J., Polman, C. H., Aalberse, R. C., Schuurman, J., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1553 · Cited by 298
Stapleton, N. M., Andersen, J. T., Stemerding, A. M., Bjarnarson, S. P., Verheul, R. C., Gerritsen, J., Zhao, Y., Kleijer, M., Sandlie, I., de Haas, M., et al. (2011) · Nature Communications · doi:10.1038/ncomms1608 · Cited by 286
In vivo Drug-Linker Stability of an Anti-CD30 Dipeptide-Linked Auristatin Immunoconjugate
Sanderson, R. J., Hering, M. A., James, S. F., Sun, M. M. C., Doronina, S. O., Siadak, A. W., Senter, P. D., & Wahl, A. F. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.843.11.2 · Cited by 285
An Engineered Human IgG1 Antibody with Longer Serum Half-Life
Hinton, P. R., Xiong, J. M., Johlfs, M. G., Tang, M. T., Keller, S., & Tsurushita, N. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.1.346 · Cited by 282
Catumaxomab: Clinical development and future directions
Linke, R., Klein, A., & Seimetz, D. (2010) · mAbs · doi:10.4161/mabs.2.2.11221 · Cited by 274
Engineered Human IgG Antibodies with Longer Serum Half-lives in Primates
Hinton, P. R., Johlfs, M. G., Xiong, J. M., Hanestad, K., Ong, K. C., Bullock, C., Keller, S., Tang, M. T., Tso, J. Y., Vásquez, M., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.c300470200 · Cited by 273
Engineering of therapeutic antibodies to minimize immunogenicity and optimize function
Presta, L. G. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.01.026 · Cited by 246
Isotype selection in antibody engineering
Salfeld, J. G. (2007) · Nature Biotechnology · doi:10.1038/nbt1207-1369 · Cited by 239
Overview of monoclonal antibodies in cancer therapy: present and promise
Stern, M., & Herrmann, R. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.10.011 · Cited by 235
Pedersen, M. W., Jacobsen, H. J., Koefoed, K., Hey, A., Pyke, C., Haurum, J. S., & Kragh, M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1417 · Cited by 219
Abulrob, A., Sprong, H., En Henegouwen, P. V. B., & Stanimirovic, D. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03463.x · Cited by 216
Synthesis and Evaluation of Hydrophilic Linkers for Antibody–Maytansinoid Conjugates
Zhao, R. Y., Wilhelm, S. D., Audette, C., Jones, G., Leece, B. A., Lazar, A. C., Goldmacher, V. S., Singh, R., Kovtun, Y., Widdison, W. C., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2002958 · Cited by 215
BiTE: Teaching antibodies to engage T-cells for cancer therapy.
Baeuerle, P. A., Kufer, P., & Bargou, R. C. (2009) · PubMed · Cited by 192
Fully human antibodies from transgenic mouse and phage display platforms
Lonberg, N. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.06.004 · Cited by 188
Engineered Antibodies of IgG1/IgG3 Mixed Isotype with Enhanced Cytotoxic Activities
Natsume, A., In, M., Takamura, H., Nakagawa, T., Shimizu, Y., Kitajima, K., Wakitani, M., Ohta, S., Satoh, M., Shitara, K., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6297 · Cited by 187
Banks, W. A., Terrell, B., Farr, S. A., Robinson, S. M., Nonaka, N., & Morley, J. E. (2002) · Peptides · doi:10.1016/s0196-9781(02)00261-9 · Cited by 185
Optimization of Fc-mediated effector functions of monoclonal antibodies
Strohl, W. R. (2009) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2009.10.011 · Cited by 168
Vaughan, T. J., Osbourn, J. K., & Tempest, P. R. (1998) · Nature Biotechnology · doi:10.1038/nbt0698-535 · Cited by 158
Impact of Glycosylation on Effector Functions of Therapeutic IgG
Abès, R., & Teillaud, J. (2010) · Pharmaceuticals · doi:10.3390/ph3010146 · Cited by 156
Nanotechnology approaches to crossing the blood-brain barrier and drug delivery to the CNS
Silva, G. A. (2008) · BMC Neuroscience · doi:10.1186/1471-2202-9-s3-s4 · Cited by 152
Bispecific Antibodies for Cancer Immunotherapy: Current Perspectives
Müller, D., & Kontermann, R. E. (2010) · BioDrugs · doi:10.2165/11530960-000000000-00000 · Cited by 137
Intrachain disulfide bond in the core hinge region of human IgG4
Bloom, J. W., Madanat, M. S., Marriott, D., Wong, T., & Chan, S. K. (1997) · Protein Science · doi:10.1002/pro.5560060217 · Cited by 130
Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates
DEGROOT, A., MCMURRY, J., & MOISE, L. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.08.002 · Cited by 109
IgG2m4, an engineered antibody isotype with reduced Fc function
An, Z., Forrest, G., Moore, R., Cukan, M. C., Haytko, P., Huang, L., Vitelli, S., Zhao, J. Z., Lü, P., Hua, J., et al. (2009) · mAbs · doi:10.4161/mabs.1.6.10185 · Cited by 104
Rutgers, K. S., Nabuurs, R. J. A., van den Berg, S. A. A., Schenk, G. J., Rotman, M., Verrips, C. T., van Duinen, S. G., Maat–Schieman, M. L. C., van Buchem, M. A., de Boer, A. G., et al. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.05.076 · Cited by 55
Boado, R. J., Lu, J. Z., Hui, E. K., & Pardridge, W. M. (2009) · Biotechnology and Bioengineering · doi:10.1002/bit.22576 · Cited by 48
Strategies for enhancing antibody delivery to the brain
Frank, R. T., Aboody, K. S., & Najbauer, J. (2011) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2011.07.002 · Cited by 48
Pharma interest surges in antibody drug conjugates
Webb, S. (2011) · Nature Biotechnology · doi:10.1038/nbt0411-297 · Cited by 40
Lü, Y., Harding, S. E., Rowe, A. J., Davis, K. G., Fish, B. C., Varley, P., Gee, C., & Mulot, S. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21016 · Cited by 21
Cited by
Antibody–drug conjugates as novel anti-cancer chemotherapeutics
Peters, C., & Brown, S. (2015) · Bioscience Reports · doi:10.1042/bsr20150089 · Cited by 492
Emerging new therapeutic antibody derivatives for cancer treatment
Jin, S., Sun, Y., Liang, X., Gu, X., Ning, J., Xu, Y., Chen, S., & Pan, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00868-x · Cited by 459
Cataldi, M., Vigliotti, C., Mosca, T., Cammarota, M., & Capone, D. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061249 · Cited by 267
Fekete, S., Guillarme, D., Sandra, P., & Sandra, K. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.5b04561 · Cited by 258
Camelid and shark single domain antibodies: Structural features and therapeutic potential
Könning, D., Zielonka, S., Grzeschik, J., Empting, M., Valldorf, B., Krah, S., Schröter, C., Sellmann, C., Hock, B., & Kolmar, H. (2017) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2016.10.019 · Cited by 214
Metadata
- Authors
- Buss, N. A., Henderson, S. J., McFarlane, M., Shenton, J. M., & de Haan, L.
- Venue
- Current Opinion in Pharmacology
- Publisher
- Elsevier BV
- Published
- 2012-10
- Volume
- 12
- Issue
- 5
- Pages
- 615-622
- ISSN
- 1471-4892 (ISSN-L)
- OpenAlex
- W2081641593
- Cited by
- 434
- References
- 56
- FWCI
- 3.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.